Related Experiment Video
Updated: Oct 20, 2025
Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma
Published on: April 25, 2025
The immunogenomic landscape of resected intrahepatic cholangiocarcinoma
Fernando Carapeto1, Behnaz Bozorgui2, Rachna T Shroff3
1Department of Translational Molecular PathologyThe University of Texas MD Anderson Cancer CenterHoustonTexasUSA.
Background And Aims:
Cholangiocarcinoma (CCA) is a deadly and highly therapy-refractory cancer of the bile ducts, with early results from immune checkpoint blockade trials showing limited responses. Whereas recent molecular assessments have made bulk characterizations of immune profiles and their genomic correlates, spatial assessments may reveal actionable insights.
Approach And Results:
Here, we have integrated immune checkpoint-directed immunohistochemistry with next-generation sequencing of resected intrahepatic CCA samples from 96 patients. We found that both T-cell and immune checkpoint markers are enriched at the tumor margins compared to the tumor center. Using two approaches, we identify high programmed cell death protein 1 or lymphocyte-activation gene 3 and low CD3/CD4/inducible T-cell costimulator specifically in the tumor center as associated with poor survival. Moreover, loss-of-function BRCA1-associated protein-1 mutations are associated with and cause elevated expression of the immunosuppressive checkpoint marker, B7 homolog 4.
Conclusions:
This study provides a foundation on which to rationally improve and tailor immunotherapy approaches for this difficult-to-treat disease.
Insights
Spatial immune profiling of intrahepatic cholangiocarcinoma (CCA) reveals distinct tumor center characteristics associated with poor survival. Understanding these spatial immune features can guide improved immunotherapy strategies for this deadly bile duct cancer.
Area of Science:
- Oncology
- Immunology
- Genomics
Background:
- Cholangiocarcinoma (CCA) is a lethal bile duct cancer with limited treatment options.
- Existing immune checkpoint blockade trials show minimal patient responses.
- Bulk molecular profiling lacks spatial resolution crucial for understanding tumor immunity.
Purpose of the Study:
- To investigate the spatial distribution of immune cells and checkpoint markers in intrahepatic CCA.
- To identify spatial immune profiles associated with patient survival outcomes.
- To explore the relationship between genetic mutations and immune evasion in CCA.
Main Methods:
- Integrated immunohistochemistry for immune checkpoint markers with next-generation sequencing.
- Analyzed 96 resected intrahepatic CCA samples.
- Compared immune marker expression at tumor margins versus the tumor center.
Main Results:
- T-cell and immune checkpoint markers were enriched at tumor margins.
- High expression of PD-1/LAG-3 and low CD3/CD4/ICOS in the tumor center correlated with poor survival.
- Loss-of-function BRCA1-associated protein-1 mutations were linked to increased B7-H4 expression.
Conclusions:
- Spatial immune profiling offers actionable insights into CCA tumor biology.
- Specific spatial immune signatures predict poor prognosis in CCA patients.
- Findings provide a basis for developing tailored immunotherapies for CCA.
